Sunday - May 25, 2025

LOGIN  |  REGISTER
Cue Biopharma
Amneal Pharmaceuticals

Perrigo to Attend the UBS 2025 Global Consumer and Retail Conference

February 26, 2025 | Last Trade: US$26.56 0.16 0.61

DUBLIN, Feb. 26, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the UBS 2025 Global Consumer and Retail Conference, on Wednesday, March 12 at 10 AM ET in New York City. 

Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts.

About Perrigo 

Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at www.perrigo.com

Forward-Looking Statements

This press release includes, and the matters discussed in Perrigo's presentation at the 2025 UBS Global Consumer and Retail Conference will include certain "forward-looking statements" within the meaning of the Private Litigation Securities Reform Act of 1995, as amended. Forward-looking statements relate to future events and involve known and unknown risks, uncertainties and other factors—many of which beyond the Company's control—that may cause the actual results, performance or achievements of the Company to be materially different from its current expectations, assumptions, estimates and projections. Interested persons are urged to consult the Company's filings with the United States Securities and Exchange Commission, available at https://investor.perrigo.com/sec-filings, for a discussion of the Company's business and financial condition and certain material trends, risks, uncertainties and other factors relating thereto, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2023.

Perrigo Investor Contact

Bradley Joseph, Vice President, Global Investor Relations & Corporate Communications;
(269) 686-3373; e-mail: bradley.joseph@perrigo.com 

Nicholas Gallagher, Senior Manager, Global Investor Relations & Corporate Communications;
(269) 686-3238, e-mail: nicholas.gallagher@perrigo.com 

Assertio

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page